GlassScriptPhysician profile
Syed Naqvi
NPI 1518037225
$3,222.31
in general payments reported to CMS, 2019-2025
19 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,453 · 2020: $711 · 2021: $444 · 2022: $16.77 · 2023: $195 · 2024: $181 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $580 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.14 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,258.36 | 2019-2021 | |
| Boston Scientific Corporation | $772.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.69 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $186.13 | 2023-2025 | Breztri, Airsupra |
| Insmed, INC. | $138.53 | 2025 | Arikayce, Brinsupri |
| Optinose US, INC. | $135.46 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $135.45 | 2024 | |
| Esperion Therapeutics, INC. | $120.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $66.68 | 2020-2023 | Xarelto |
| Abbvie INC. | $45.62 | 2024 | |
| Corcept Therapeutics | $25.17 | 2021 | |
| Merck Sharp & Dohme LLC | $22.87 | 2020 | |
| Tandem Diabetes Care, INC. | $21.73 | 2020 | |
| Genentech USA, INC. | $20.50 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.77 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cmp Pharma, INC. | $15.10 | 2023 | Norliqva, Tadliq, Carospir |
| Mannkind Corporation | $15.09 | 2021 | |
| Ibsa Pharma INC. | $14.10 | 2020 | |
| Glaxosmithkline, LLC. | $13.27 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Naqvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.